Bitler et al. used this approach to identify EZH2 methyltransferase as a novel target in ARID1A-mutated ovarian cancers, and EZH2 inhibition has since been explored as a viable therapy in other cancers with ARID1A mutations (Bitler et al., 2015; Alldredge and Eskander, 2017; Ferguson et al., 2021; Yamada et al., 2021). This evidence concerns the gene ARID1A and ovarian carcinoma.